- Q1 2024 BioArctic AB Earnings Call TranscriptMay 17, 2024$21.7 (-1.05%)Earnings
- Q4 2023 BioArctic AB Earnings Call TranscriptFeb 14, 2024$19.03Earnings
- Q3 2023 BioArctic AB Earnings Call TranscriptNov 08, 2023$19.64 (-1.13%)Earnings
- Q2 2023 BioArctic AB Earnings Call TranscriptJul 12, 2023$27.16Earnings
- Q1 2023 BioArctic AB Earnings Call TranscriptApr 27, 2023$27.94Earnings
- Q4 2022 BioArctic AB Earnings Call TranscriptFeb 03, 2023$25.25Earnings
- Q3 2022 BioArctic AB Earnings Call TranscriptOct 20, 2022Earnings
- Q2 2022 BioArctic AB Earnings Call TranscriptJul 12, 2022Earnings
- Q1 2022 BioArctic AB Earnings Call TranscriptApr 28, 2022Earnings
- Q4 2021 BioArctic AB Earnings Call TranscriptFeb 03, 2022Earnings
- Q3 2021 BioArctic AB Earnings Call TranscriptOct 21, 2021Earnings
- Q2 2021 BioArctic AB Earnings Call TranscriptJul 09, 2021Earnings
- Q1 2021 BioArctic AB Earnings Call TranscriptApr 21, 2021Earnings
- Full Year 2020 BioArctic AB Earnings Call TranscriptFeb 04, 2021Earnings
- Nine Months 2020 BioArctic AB Earnings Call TranscriptOct 14, 2020Earnings
- Q2 2020 BioArctic AB Earnings Call TranscriptJul 10, 2020Earnings
- Q1 2020 BioArctic AB Earnings Call TranscriptApr 22, 2020Earnings
- Full Year 2019 BioArctic AB Earnings Call TranscriptFeb 06, 2020Earnings
- Q3 2019 BioArctic AB Earnings Call TranscriptOct 24, 2019Earnings
- Q2 2019 BioArctic AB Earnings Call TranscriptJul 11, 2019Earnings
- Q1 2019 BioArctic AB Earnings Call TranscriptMay 09, 2019Earnings
- Full Year 2018 BioArctic AB Earnings Call TranscriptFeb 14, 2019Earnings
Q3 2021 BioArctic AB Earnings Call Transcript
Hello, and welcome to the BioArctic webcast with teleconference. (Operator Instructions) Just to remind you, this conference call is being recorded. Today, I'm pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please go ahead with your meeting.
()-
Thank you, and good morning, and welcome to BioArctic's Third Quarter Report 2020. I I'm Gunilla Osswald and I'm the CEO of BioArctic. I will share this presentation with our CFO, Jan Mattsson. I think it has been a great quarter for BioArctic and lecanemab. Our partner, Eisai, has after discussions with the U.S. FDA initiated a rolling submission for an accelerated approval for lecanemab in the U.S.
If it gets approved, lecanemab could thereby potentially be helping patients even earlier than previously expected, and I will talk more about that in the presentation here today. Next slide, please. BioArctic is listed on nasdaq.com midcap, and this is our disclaimer. Next slide, please.
BioArctic is a unique Swedish
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)